Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection

Kun Li,a Zhuo Li,d*, Christine Wohlford-Lenane,a David K. Meyerholz,b Rudragouda Channappanavar,c, d* Dong An,d Stanley Perlman,a,c Paul B. McCray, Jr.,a,c Biao Hea

aDepartment of Pediatrics, Pappajohn Biomedical Institute, University of Iowa, Iowa City, Iowa, USA
bDepartment of Pathology, University of Iowa, Iowa City, Iowa, USA
cDepartment of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, USA
dDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA

ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) can cause severe and fatal acute respiratory disease in humans and remains endemic in the Middle East since first being identified in 2012. There are currently no approved vaccines or therapies available for MERS-CoV. In this study, we evaluated parainfluenza virus 5 (PIV5)-based vaccine expressing the MERS-CoV envelope spike protein (PIV5-MERS-S) in a human DPP4 knockin C57BL/6 congenic mouse model (hDPP4 KI). Following a single-dose intranasal immunization, PIV5-MERS-S induced neutralizing antibody and robust T cell responses in hDPP4 KI mice. A single intranasal administration of 10^4 PFU PIV5-MERS-S provided complete protection against a lethal challenge with mouse-adapted MERS-CoV (MERS MA6.1.2) and improved virus clearance in the lung. In comparison, single-dose intramuscular immunization with 10^6 PFU UV-inactivated MERS MA6.1.2 mixed with Imject alum provided protection to only 25% of immunized mice. Intriguingly, an influx of eosinophils was observed only in the lungs of mice immunized with inactivated MERS-CoV, suggestive of a hypersensitivity-type response. Overall, our study indicated that PIV5-MERS-S is a promising effective vaccine candidate against MERS-CoV infection.

IMPORTANCE MERS-CoV causes lethal infection in humans, and there is no vaccine. Our work demonstrates that PIV5 is a promising vector for developing a MERS vaccine. Furthermore, success of PIV5-based MERS vaccine can be employed to develop a vaccine for emerging CoVs such as SARS-CoV-2, which causes COVID-19.

KEYWORDS COVID-19, MERS, coronavirus, vaccine
**RESULTS**

**Construction of a PIV5 vector expressing MERS-CoV spike glycoprotein.** Previously, we inserted the HA gene of influenza A virus at different locations within the genome of PIV5 and found that the insertion at SH and HN generates the best immune responses (24). Thus, we inserted the full-length gene of S of MERS at the SH and HN junction. A plasmid containing full-length PIV5 cDNA with the S gene insertion at SH and HN junction was constructed using standard molecular cloning techniques (Fig. 1A). The plasmid was transfected into BHK cells along with plasmids expressing T7 RNA polymerase, NP, P, and L of PIV5, and infectious virus PIV5-MERS-S was rescued as described before (24). The rescued virus was plaque-purified and then expanded to large quantity in MDBK cells for further analysis. The viral genome was sequenced and confirmed to contain the desired input DNA sequence. To verify S protein expression in PIV5-MERS-S-infected cells, the cells were infected at different MOIs and then lysed for immunoblotting using anti-S antibody. The full-length S and cleaved S2 fragments were observed in PIV5-MERS-S-infected cells, suggesting that the S protein was properly processed (Fig. 1B). Expression of S protein in PIV5-MERS-S-infected cells was further confirmed by immunofluorescence assay (Fig. 1C). Interestingly, PIV5-MERS-S caused massive syncytium formation in Vero cells. PIV5-MERS-S had a similar growth kinetics as wild-type PIV5 (Fig. 1D).
Immunization with PIV5 Expressing MERS-CoV Spike

Immunization with PIV5 MERS-S generates neutralizing antibodies and T cell-mediated immunity. To determine whether PIV5-MERS-S can generate immune responses in mice, C57BL/6 mice were immunized with a single dose of PIV5-MERS-S or control PIV5-GFP virus at 10^4 PFU or 10^6 PFU per mouse via intranasal route. While both doses generated antibody responses, neutralizing titers were modest at 1:64 and 1:128 for the 10^4 and 10^6 doses, respectively (Fig. 2A and B). It is known that C57BL/6 and BALB/c mice generate Th1- and Th2-dominant immune responses, respectively, following immunization. A single dose of 10^6 PFU of PIV5-MERS-S resulted in a neutralization antibody titer as high as 1:2,000 in BALB/c mice (Fig. 2C), consistent with a Th2-dominant response in BALB/c mice.

To assess the primary CD8 T cell response generated by PIV5-MERS-S immunization, hDPP4-KI mice were intranasally immunized with 10^4 PFU PIV5-MERS-S. Four weeks later, lungs were harvested and examined for MERS-CoV-specific lung-resident CD8 T cells (Fig. 3A). As shown in Fig. 3B to D, we observed a significant increase in the
percentage and total number of CD8^+/-IFN-γ^+ cells in the lungs of PIV5-MERS-S-immunized mice in comparison to those infected with PIV5-GFP virus, consistent with a MERS-S-specific primary CD8 T cell response in the lungs. Further, to examine recall response of MERS-S-specific CD8 T cells, we challenged PIV5-MERS-S- and PIV5-GFP-immunized mice with 10^4 PFU of MERS-CoV MA6.1.2. Our results show a significant increase in the recall CD8 T cell response at day 4 p.i. in comparison to PIV5-GFP-immunized mice (Fig. 3E to G). We also observed 10-fold increase in MERS-S-specific CD8 T cells compared to the primary CD8 T cell response (Fig. 3B to G). Collectively, these results indicate that MERS-S immunization induces a significantly increased MERS-S-specific CD8 T cell response upon PIV5-MERS-S immunization.

Immunization with PIV5-MERS-S prevents lethal infection in mice. To determine the efficacy of PIV5-MERS-S in preventing or modifying a MERS-CoV infection, hDPP4 KI mice on the C57BL/6 background were immunized with 10^4 PFU PIV5-MERS-S via the intranasal route. At 4 weeks after immunization, mice were challenged with a mouse-adapted MERS-S strain (Fig. 4A). All PIV5-MERS-S-immunized mice survived this lethal challenge and lost little weight (Fig. 4B and C). In contrast, PIV5-GFP- or PBS-immunized mice all died following challenge (Fig. 4B and C), indicating that PIV5-MERS-S completely protected mice against lethal challenge. While PIV5-MERS-S-immunized mice had a higher rate of virus clearance from the lungs, this did not provide sterilizing immunity (Fig. 4D).

Histopathology of lung tissues. Histopathology studies of lungs after challenge with MERSMA6.1.2 indicated that PIV5-MERS-S-immunized mice had significantly less cellular debris present and greater mononuclear infiltrates (Fig. 5A and B). PIV5-MERS-S-immunized mice exhibited robust cellular infiltration of leukocytes (mostly mononuclear cells) and less evidence of lesions (edema, hyaline membranes, necrotic cellular debris, etc.) indicative of severe disease (Fig. 5).

Comparison of PIV5-MERS-S to inactivated MERS-CoV. To investigate the protective responses elicited by PIV5-MERS-S and the inactivated MERS-CoV, hDPP4 KI mice on the C57BL/6 background were immunized with 10^4 PFU of PIV5-MERS-S or PBS via i.m. route. While PIV5-MERS-S provided 100% protection against lethal challenge, inactivated MERS-CoV protected 25% of mice from mortality (Fig. 6).

It has been reported that mice immunized with inactivated SARS-CoV and MERS-CoV developed a hypersensitivity-type response after respective SARS-CoV and MERS-CoV challenge, manifested by increased IL-4 and IL-5 expression and an influx of eosinophils (29). We examined the lungs of mice that were immunized and then challenged with MERS-CoV (Fig. 7). We observed more eosinophils in the lungs of mice immunized with inactivated MERS-CoV than in PBS- or PIV5-MERS-S-immunized mice following MERS-CoV challenge. Compared to PBS, perivascular eosinophilic infiltration was significantly increased in the inactivated MERS-CoV group, but no statistical difference was seen.
when compared with the PIV5-MERS-S-immunized group. In these same lung tissues, we evaluated hyaline membrane formation as a measure of diffuse alveolar damage. Compared to the PBS group, the PIV5-MERS-S-immunized mice demonstrated significant protection against hyaline membrane formation, while the inactivated MERS-CoV group had only minor nonsignificant reductions in hyaline membrane formation. These results suggest that inactivated MERS-CoV may have caused a hypersensitivity-type response, while PIV5-MERS-S-immunized mice had minimal lung influx of eosinophils and were protected.

**DISCUSSION**

Many strategies have been considered to develop vaccines for both SARS-CoV and MERS-CoV. A live attenuated SARS-CoV with rationally introduced mutations was efficacious in golden Syrian hamsters (30). However, the development of a live attenuated vaccine for a positive-stranded RNA virus like SARS-CoV has often been hampered by safety concerns. Several MERS vaccine candidates are under investigation. A DNA-based vaccine expressing the full-length S protein is the most advanced to date (31); it is well tolerated in humans, as shown in a phase I clinical trial. The prime-boost regimen of MVA (Modified Vaccinia Ankara) expressing MERS S protein induced neutralizing antibodies and T cell responses in mice and limited viral replication after challenge in mice and camels. However, MVA-S did not provide sterilizing immunity.
and infectious MERS-CoV and genomic RNA were detected after challenge in mice and camels (32, 33). The prime-boost regimen of measles virus (MV) expressing MERS S or soluble S induced both humoral and cellular immune responses. After MERS challenge, infectious MERS-CoV or genomic RNA significantly decreased, but these two vaccines did not provide sterilizing immunity, and signs of inflammation were observed in mouse lung tissue (34). An inactivated rabies virus (RABV) expressing MERS S1 provided complete protection from MERS challenge in mice but three 10-μg doses of vaccine were needed (35). Furthermore, the Ad5/hDPP4-transduced mouse model used in these studies has limitations. Adenovirus (Ad5) expressing MERS S or S1 also induced a neutralizing antibody in mice (36). Ad41, an enteric adenovirus, may induce enhanced mucosal immunity when administered via an oral or intragastric (i.g.) route (37, 38). However, i.g. immunization of both Ad41-S and Ad5-S failed to generate mucosal immunity. Although Ad41-S induced humoral immunity in serum, it was significantly less than Ad5-S (39). Chimpanzee adenovirus-based vector systems have also been used (40). In our work, we demonstrated that a single dose as low as 10⁴ PFU of PIV5-MERS-S was sufficient to provide 100% protection against lethal MERS-CoV challenge. The low dose is especially advantageous in a situation where a mass immunization program is needed in a short period of time. To the best of our knowledge, this is the most efficacious MERS-CoV vaccine tested in a relevant animal model.

The protective mechanism of PIV5-MERS-S vaccine in C57BL/6 mice is likely due to robust cellular immune responses after PIV5-MERS-S immunization. While neutralizing antibody was generated in C57BL/6 mice after a single-dose immunization with PIV5-MERS-S, titers were modest at 1:64 and 1:128 with 10⁴ PFU and 10⁶ PFU of PIV5-MERS-S, respectively (Fig. 2A and B). Consistent with protective cellular immune responses protecting the mice, a significant influx of CD8⁺ IFN-γ⁺ cells was detected in lungs of C57BL/6 mice following PIV5-MERS-S immunization (Fig. 3). Furthermore, the observation that PIV5-MERS-S-immunized mice had a higher rate of MERS virus clearance (Fig. 4C) suggests a role for T cell-based immunity in protecting C57BL/6 mice against lethal challenge. Interestingly, in BALB/c mice, PIV5-MERS-S generated neutralizing antibody titers as high as 1:2,000 (Fig. 2C). It is possible that the higher neutralizing antibody titers in BALB/c mice may be protective. Unfortunately, the only available small animal model is a humanized mouse model on the C57BL/6 background. It is known that the S protein is a major protective antigen for coronaviruses. It may be

FIG 4 Single-dose intranasal immunization with PIV5-MERS-S completely protects hDPP4 KI mice from lethal MERS-CoV challenge. (A) Schematic timeline showing immunization, challenge, and the evaluation of protection. hDPP4 KI mice were intranasally immunized with 10⁴ PFU PIV5-MERS-S, PIV5-GFP, or PBS. Four weeks after immunization, the mice were intranasally infected with 10⁵ PFU MERSMA6.1.2. (B and C) Survival (B) and weight loss (C) were monitored daily for 12 days. PIV5-MERS-S or PIV5-GFP, n = 10; PBS, n = 5. (D) At indicated days postinfection, virus lung titers were quantified by plaque assay. Data are representative of two independent experiments. Data presented represent mean ± SE; * denotes P < 0.05 and ** denotes P < 0.01, Mann-Whitney test. LOD, limit of detection.
possible to improve our vaccine efficacy by expressing additional MERS-CoV proteins such as N and M using PIV5 as a vector. However, a parainfluenza virus 3 (PIV3)-based SARS-CoV vaccine candidate expressing N, M, or E without the S protein failed to protect hamsters from SARS-CoV challenge (41). The ability of PIV5-MERS-S to generate cellular and humoral immune responses in mice may be in part attributed to the ability of PIV5 to express the MERS S protein in its native conformation. As shown in Fig. 1C, PIV5-MERS-S caused massive syncytium formation in Vero cells, indicating the S protein was functional in promoting cell-to-cell fusion. Thus, we reasoned that the S protein produced in PIV5-MERS-S-infected cells maintains a native conformation.

The MERS S protein has 1,353 amino acid residues. The entire insertion of the S gene with proper regulatory sequences is over 4,000 nucleotides in length. This is the longest single gene we have inserted into the PIV5 genome. Since we inserted this gene between SH and HN, and the SH gene is not essential, it may be possible to remove SH to allow insertion of longer sequences. Thus, we speculate that the PIV5 genome can accommodate sequences longer than 4,000 nucleotides.

It has been reported that inactivated SARS-CoV-immunized mice generated a hypersensitive-type lung pathology after virus challenge, raising the concern of vaccine-enhanced disease (42, 43). Previously, a formalin-inactivated, whole-virus respiratory syncytial virus (RSV) vaccine caused enhanced disease in vaccinated children, leading to vaccine-related deaths (44). Similarly, inactivated MERS-CoV has been reported to generate a Th2-type immunopathology after MERS-CoV challenge in mice (29). In the case of a PIV5-based RSV vaccine, extensive studies indicate that PIV5-based RSV vaccine does not cause enhanced diseases (45). Thus, as a viral vector, PIV5 is not known to cause any enhanced diseases, and in our experiment, we observed no abnormal immune responses in PIV5-MERS-S-immunized mice after MERS-CoV challenge, suggesting that PIV5-MERS-S is unlikely to be associated with enhanced disease.
Lung tissues of mice immunized with inactivated MERS-CoV had an influx of eosinophils after MERS-CoV challenge, indicative of a hypersensitivity-type response. This result is consistent with a previous report that inactivated MERS-CoV immunization caused increased IL-4 and IL-5 expression and an influx of eosinophils in lungs after challenge (29). Understanding whether immunization with inactivated MERS-CoV can cause enhanced disease is critical for developing a safe and effective vaccine.

While MERS-CoV has a high morbidity and mortality, it has a very low prevalence in human populations. Dromedary camels are considered the intermediate host that transmits MERS-CoV to humans. Thus, it may be possible to control the spread of MERS-CoV in humans by controlling infection in dromedary camels. Perhaps virus transmission from camels to humans can be blocked, with concomitant immunization of high-risk human populations, as proposed by CEPI (The Coalition for Epidemic Preparedness Innovations) and WHO. As a vaccine vector, PIV5 has been effective in mice, cotton rats, hamsters, guinea pigs, ferrets, dogs, and nonhuman primates (25, 46–49). It will be worthwhile to test PIV5-MERS-S in camels in the future.

Recently, SARS-CoV-2 (2019-nCoV) was identified in Wuhan, China, in late 2019. This is a novel zoonotic CoV related to the SARS-CoV that can cause severe respiratory disease (COVID-19). To date, this virus resulted in a significant disease burden, with more than 465,000 cases reported in 199 countries and an estimated case fatality rate of ~2%. The finding that PIV5 expressing MERS S protected mice against lethal MERS-CoV challenge at a single low dose of 10^4 PFU suggests its potential use as a vaccine vector for emerging viruses such as SARS-CoV-2. Further studies of using PIV5 expressing the S protein from SARS-CoV-2 as a vaccine candidate are ongoing.

MATERIALS AND METHODS

Cells. Vero cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 IU/ml penicillin, and 100 μg/ml streptomycin (1% P/S; Mediatech Inc., Manassas, VA, USA). BHK21 cells were maintained in DMEM containing 10% tryptose phosphate broth (TPB), 10% fetal bovine serum (FBS), 100 IU/ml penicillin, and 100 μg/ml streptomycin. MDBK cells were grown in DMEM containing 5% FBS and 1% P/S. Cells were prepared 1 day prior to infection, achieving approximately 90% confluence by the following day.

Viruses. The plasmid containing the cDNA clone of PIV5 with MERS-S inserted between SH and HN was constructed using previously described methods (22, 26, 29). Primer sequences are available upon
request. Infectious virus was rescued in BHK cells as previously described (26). Recombinant PIV5 or PIV5-MERS-S was propagated in MDBK cells as previously described (26, 29).

PIV5 plaque assays were performed as previously described (24). Briefly, 10-fold serial dilutions were prepared in DMEM with 1% BSA. One hundred microliters of each dilution was transferred to 6-well plates of BHK21 cells, in a total infection volume of 1 ml. After adsorption for 1 to 2 h at 37°C, 5% CO2, the inocula were aspirated, and cell monolayers were overlaid with DMEM containing 10% tryptose phosphate broth (TPB), 2% FBS, 1% P/S, and 1% low-melting-point agarose. After 5 days, the cells were fixed with 2% formaldehyde, overlays were removed, and the cells were stained with crystal violet to visualize the plaques.

To obtain virus titers in lung tissues, lungs of infected mice were removed at the indicated days after challenge and homogenized in PBS using a manual homogenizer. Virus titer was determined in Vero 81 cells by plaque assay. Infected Vero 81 cells were fixed in 25% formaldehyde and stained with 0.1% crystal violet to delineate plaques.

To determine growth rates of PIV5 and PIV5-MERS-S, MDBK cells were infected with PIV5 or PIV5-MERS-S at an MOI of 0.1. After adsorption for 1 to 2 h at 37°C, 5% CO2, DMEM with 2% FBS and 1% P/S was added to the plates. One-hundred-microliter samples of supernatant were collected daily for 5 days and frozen at -80°C. Virus titers in the samples were quantified by plaque assay.

Immunization and infection of mice. Specific-pathogen-free 6-week-old C57BL/6 and BALB/c mice were purchased from Charles River Laboratory (CR). Specific-pathogen-free human DPP4 knockin (hDPP4 KI) mice were generated on a C57BL/6 background as previously reported (50). All mice were bred and maintained in the University of Iowa animal care facility. All protocols were reviewed and approved by the University of Iowa Institute Animal Care and Use Committee. Six- to 8-week-old male and female mice were used for these studies. Mouse-adapted MERS-CoV strain MERSa6.1.2 was generated as reported earlier (50).

Mice were anesthetized with xylazine-ketamine (97.5 mg/kg of body weight ketamine, 12.5 mg/kg xylazine) and infected intranasally with 104 PFU or 106 PFU PIV5-MERS-S or PIV5-GFP in 60 μl DMEM. The mouse-adapted MERSa6.1.2 strain was inactivated by exposure to UV light for 1 h using a wattage of 4,016 μW/cm2. Then 104 PFU UV-inactivated viruses were 1:1 (vol/vol) mixed with Imject alum (Thermo, catalog no. 77161) and delivered to mice intramuscularly. Four weeks postimmunization, mice were infected intranasally with 106 PFU PIV5-MERS-S or PIV5-GFP in 60 μl DMEM. The mouse-adapted MERSa6.1.2 strain was inactivated by exposure to UV light for 1 h using a wattage of 4,016 μW/cm2. Then 104 PFU UV-inactivated viruses were 1:1 (vol/vol) mixed with Imject alum (Thermo, catalog no. 77161) and delivered to mice intramuscularly. Four weeks postimmunization, mice were infected intranasally with 105 PFU PIV5-MERS-S or PIV5-GFP in 60 μl DMEM. For passive immunization, sera were collected from hDPP4 KI mice that received 104 PFU PIV5-MERS-S or PIV5-GFP intranasally at 4 weeks postimmunization. Two hundred microliters of sera were transferred into hDPP4 KI mice intraperitoneally 1 day before challenge with 106 PFU PIV5-MERS-S. Infected mice were examined daily, and weights were recorded. All work with MERS-CoV was performed in the biosafety level 3 (BSL3) laboratory of the University of Iowa.

FIG 7 Representative images of lung tissues from mice receiving PBS (A), UV-inactivated MERS-CoV (B), or PIV5-MERS-S (C) treatment, followed by infection with MERSa6.1.2. Images obtained from tissues at 3 days after MERSa6.1.2 infection. Compared to PBS or PIV5-MERS, perivascular eosinophilic infiltration (arrows) in UV-MERS-treated mice was greatly increased. n = 3 to 4 mice/group. (D) Graph representing eosinophil infiltration in the lung tissues of mice from groups shown in panels A to C. * denotes P < 0.009, Dunn’s posttest. Other group comparisons were not significant. (E) Graph representing hyaline membranes in the lung tissues of mice from groups shown in panels A to C. * denotes P < 0.0065, Dunn’s posttest. Other group comparisons were not significant.
Histology. At the indicated days postchallenge, mice were anesthetized and perfused with PBS by intracardiac injection followed by perfusion with zinc formalin. Lungs were removed, fixed in zinc formalin overnight, and paraffin embedded. Lung sections (~4-μm thickness) were stained with hematoxylin and eosin. Tissues were evaluated by board-certified veterinary pathologists and scored using a postexamination masking method (51). Lungs were scored for edema, hyaline membranes, cellular debris, and hemorrhage, with scores of 0, 1, 2, 3, and 4 representing detection in 0%, less than 5%, 6% to 33%, 33% to 66%, and more than 66% of lung fields, respectively. Lungs were scored for mononuclear infiltrates, with scores of 0 representing values within normal parameters, 1 representing small aggregates in peribronchial and perivascular areas, 2 representing perivascular and periairway aggregates filling perivascular space, and 3 representing a score of 2 plus expanding sheets of infiltrates into septa and consolidation lesions in regions of the lung, respectively. Lungs were scored for granulocytic infiltrates, with scores as follows: 0, within normal parameters; 1, scattered PMNs sequestered in septa; 2, a score of 1 plus solitary PMNs extravasated in airspaces; 3, a score of 2 plus small aggregates in vessels and airspaces, respectively. Lung tissues were evaluated for perivascular eosinophil infiltration. Briefly, vessels with cellular infiltration (n = 20/lung) were randomly selected by a masked pathologist, and the number of eosinophils was enumerated and averaged for a final score for each lung (52).

Neutralizing antibody assay. Four weeks postimmunization, sera from immunized mice were collected. All serum samples were heat inactivated by incubation at 56°C for 30 min. Heat-inactivated serum was serially diluted by 2-fold in 96-well plates before the same volume of MERS-CoV pseudovirus was added and incubated at 37°C for 1 h. The mixture was added into Vero E1 cells in 96-well plates and incubated at 37°C for 1 h to allow virus binding. Then the mixture was removed, and cells were rinsed with PBS. The next day, the neutralization results were measured by luciferase assay and plotted relative to the value for serum-free wells.

Immunoblotting and immunofluorescence. Vero 81 cells were infected with PIV5-MERS-S at different MOIs or mock infected at 37°C for 1 h. Cell lysates were collected at 2 days postinfection and applied to Western blotting. The expression of MERS-CoV spike protein was detected by a rabbit anti-MERS-CoV S2 antibody (Sino Biological, catalog no. 40070-T60) and colocalized using a mouse anti-α-tubulin antibody (Sigma, catalog no. T9026). Indirect immunofluorescence assays were performed to detect expression of the S protein in PIV5-MERS-S-infected cells. Vero cells were infected with PIV5 or PIV5-MERS-S. Forty-eight hours later, cells were fixed with 2% formaldehyde in phosphate-buffered saline (PBS) and permeabilized by adding 0.1% saponin to the immunostaining buffers. Anti-MERS-S from Sino Biological was used (catalog no. 40070-T60). The cells were imaged using a Nikon A1R confocal microscope.

Analyses of MERS-CoV-specific CD8 T cell response. hDPP4 KI mice were immunized with 10⁴ PFU PIV5-GFP or PIV5-MERS-S via intranasal route. At 4 weeks postimmunization, lung cells were harvested and MERS-CoV-specific CD8+ T cells were stimulated with 1 μM S434 and S1165 peptides as described previously (53) in the presence of Golgi-plug (1 μl/ml) for 5 h. Cells were then washed and stained for cell surface CD45, CD4, and CD8 markers followed by intracellular IFN-gamma staining. To examine the recall CD8 T cell response, hDPP4 KI mice immunized with 10⁴ PFU PIV5-GFP or PIV5-MERS-S via intranasal route were challenged with 10¹ PFU MERSm极为6.1.2. Four days after MERSm极为6.1.2 infection, lungs were harvested and CD8+ T cells were stimulated with S434 and S1165 peptides in the presence of Golgi-plug (1 μl/ml) for 5 h. Cells were then washed and stained for cell surface CD45, CD4, and CD8 markers followed by intracellular IFN-gamma staining. The following monoclonal antibodies were used: PECy7 anti-CD45 (30-F11), anti-CD4 (RM4-5), and anti-CD8α (53-6.7), all from BD Bioscience, and IFN-γ (XMG1.2) from ebioscience.

ACKNOWLEDGMENTS

We thank the members of the Perlman, McCray, and He laboratories for their helpful discussion and technical assistance.

This work is supported by the National Institutes of Health (NIH) grant P01 AI060699 and the Cell Morphology Core and Pathology Core, which are partially supported by the Center for Gene Therapy for Cystic Fibrosis (NIH grant P30 DK-54759), and the Cystic Fibrosis Foundation. P.B.M. is supported by the Roy J. Carver Charitable Trust. B.H. is supported by the Fred C. Davison Distinguished University Chair in Veterinary Medicine. B.H. is an inventor and holds a patent “Parainfluenza virus 5-based vaccines,” which is owned by the University of Georgia Research Foundation (UGARF). CyanVac LLC, which was founded by B.H., has licensed the IP from UGARF for the development of PIV5-based vaccines.

REFERENCES

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814–1820. https://doi.org/10.1056/NEJMoa1211721.
2. Yusof MF, Eltahir YM, Serhan WS, Hashem FM, Elsayed EA, Marzoug BA, Abdelazim AS, Bensonah OK, Al Muhairi SS. 2015. Prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Abu Dhabi Emirate, United Arab Emirates. Virus Genes 50:509–513. https://doi.org/10.1007/s11262-015-1174-0.
3. Chan RW, Hemida MG, Kayali G, Chu DK, Poon LL, Alnaeeem A, Ali MA, Tao
Immunization with PIV5 Expressing MERS-CoV Spike

11. S. B. 2017. Genetic stability of parainfluenza virus 3-vegetated human respir-atory syncytial virus vaccine candidates after in vitro and in vivo pas-sage. J Virol 91:e00559-17. https://doi.org/10.1128/JVI.00559-17.

22. Tompkins SM, Lin Y, Leser GP, Kramer KA, Haas DL, Howerty EW, Xu J, Kennett MJ, Durbin RK, Durbin JE, Tripp R, Lamb RA, He B. 2007. Reombinant parainfluenza virus 5 (PIVs) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology 362:139–150. https://doi.org/10.1016/j.virol.2006.12.005.

23. Mooney AJ, Li Z, Gabbard JB, He B, Tompkins SM. 2013. Reombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinion protects against H5N1 highly pathogenic avian influenza virus in-fection following intranasal or intramuscular vaccination of BALB/c mice. J Virol 87:356–371. https://doi.org/10.1128/JVI.02330-12.

24. Li Z, Mooney AJ, Gabbard JD, Gao X, Xu P, Place RJ, Hogan RJ, Tompkins SM, He B. 2013. Reombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge. J Virol 87:354–362. https://doi.org/10.1128/JVI.02321-12.

25. Li Z, Gabbard JD, Mooney A, Gao X, Chen Z, Place RJ, Tompkins SM, He B. 2013. Single dose vaccination of a reombinant parainfluenza virus 5 expressing NP from H5N1 provides broad immunity against influenza A virus infection. J Virol 87:5899–5906. https://doi.org/10.1128/JVI.00310-13.

26. Li Z, Gabbard JD, Mooney A, Chen Z, Tompkins SM, He B. 2013. Efficacy of parainfluenza virus 5 mutants expressing HA from H5N1 influenza A virus in mice. J Virol 87:9604–9609. https://doi.org/10.1128/JVI.01289-13.

27. Phan S, Chen Z, Xu P, Li Z, Gao X, Foster SL, Teng MN, Tripp RA, Sakamoto K, He B. 2014. A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5). Vaccine 32:3050–3057. https://doi.org/10.1016/j.vaccine.2013.06.046.

28. Chen Z, Zhou M, Gao X, Zhang G, Ren G, Gnanadurai CW, Fu ZF, He B. 2013. A novel rabies vaccine based on a reombinant parainfluenza virus 5 expressing rabies virus glycoprotein. J Virol 87:2986–2993. https://doi.org/10.1128/JVI.02886-12.

29. Agrawal AS, Tao X, Alagiasi A, Garnon T, Narayanakan K, Peng BH, Couch RB, Tseng CT. 2016. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on chal-lenge with live virus. Hum Vaccin Immunother 12:2351–2356. https://doi.org/10.1080/21645515.2016.1177688.

30. Lamiarde EW, DeDiego ML, Roberts A, Jackson JP, Alvarez E, Sheahan T, Shieh WJ, Zaki SR, Baric R, Enjuanes L, Subbarao K. 2008. A live attenuated severe acute respiratory syndrome coronavirus is immuno-genic and efficacious in golden Syrian hamsters. J Virol 82:7721–7724. https://doi.org/10.1128/JVI.00561-08.

31. Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolini K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamerre C, Zaidi F, Boyer J, Kudchoduskar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN. 2019. Safety and immuno- genity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label single-arm, dose-escalation trial. Lancet Infect Dis 19:1013–1022. https://doi.org/10.1016/S1473-3099(19)30266-X.

32. Haagmans BL, van den Brand JM, Raj VS, Volz A, Wohlein P, Smits SL, Schipper D, Besterbroer TM, Okba N, Fux R, Bensaid A, Solanes Foz D, Kuiken T, Baumberg W, Segales J, Sutter G, Osterhaus AD. 2016. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351:77–81. https://doi.org/10.1126/science.aad1283.

33. Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, Schmidt J, Becker T, Shieh WJ, Zaki SR, Laban J, van der Hoek A. 2014. Single dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 provides broad immunity against influenza A virus infection. J Virol 87:5899–5906. https://doi.org/10.1128/JVI.00310-13.

34. Malczyk AH, Kupke A, Prüfer S, Schuepplin VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Züker Y, Seifried J, Hanschmann K-M, Kalinke U, Herold S, Sahin U, Chikutke T, Wailerbr Z, Eickmann M, Becker S, Mühlebach MD. 2015. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol 89:11654–11667. https://doi.org/10.1128/JVI.01415-15.

35. Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Friedman MB, Schnell MJ. 2017. One-Health: a safe,
efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus. J Virol 91:e02040-16. https://doi.org/10.1128/JVI.02040-16.

36. Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A. 2014. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine 32:5975–5982. https://doi.org/10.1016/j.vaccine.2014.08.058.

37. Neutra MR, Kozlowski PA. 2006. Mucosal vaccines: the promise and the problematic. Nat Rev Immunol 6:148–158. https://doi.org/10.1111/nri.12462.

38. Alharbi NK, Qasim I, Almasoud A, Aljami HA, Alenazi MW, Alhafufi A, Aldibasi OS, Hashem AM, Kasem S, Albrahim R, Aldubaib M, Almansour A, Tempertton NJ, Kupke A, Becker S, Abu-Obaibid A, Alkarar A, Yoon IK, Ahsa E, Lambe T, Bayoumi F, Aldoverij A, Ibrahim OH, Gilbert SC, Bakhly HH. 2019. Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels. Sci Rep 9:16292. https://doi.org/10.1038/s41598-019-52730-4.

39. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL. 2004. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A 101:9804–9809. https://doi.org/10.1073/pnas.0403492101.

40. Meng F, Timms E, Hung T, Luan H, Li J, Yu W, Zou X, Wang W, Z感受到 c W, Yu K, Collins PL. 2018. Principles and approaches for reproducible scoring of tissue stains in research. Lab Invest 98:844–855. https://doi.org/10.1038/s41374-018-0057-0.

41. Bolles M, Deming D, Long K, Agnihotram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. 2011. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 85:12201–12215. https://doi.org/10.1128/JVI.06048-11.

42. Anderson LJ. 2013. Respiratory syncytial virus vaccine development. Semin Immunol 25:160–171. https://doi.org/10.1016/j.smim.2013.04.011.

43. Li et al. 2013. Respiratory syncytial virus vaccine development. Semin Immunol 25:160–171. https://doi.org/10.1016/j.smim.2013.04.011.